Sanofi’s Sutimlimab Shows Promise In Rare Blood Disorder

First-In-Class Complement Pathway Inhibitor Impresses In Cold Agglutinin Disease

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.